Chlorpromazine hydrochloride
GPTKB entity
Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antipsychotic medication |
| gptkbp:ATCCode |
N05AA01
|
| gptkbp:belongs_to_class |
phenothiazines
|
| gptkbp:CASNumber |
69-09-0
|
| gptkbp:cause |
QT prolongation
neuroleptic malignant syndrome tardive dyskinesia |
| gptkbp:chemicalFormula |
C17H20ClN3S·HCl
|
| gptkbp:contraindication |
gptkb:pheochromocytoma
bone marrow depression severe CNS depression |
| gptkbp:discoveredBy |
gptkb:Paul_Charpentier
|
| gptkbp:eliminationHalfLife |
16-30 hours
|
| gptkbp:excretion |
urine
bile |
| gptkbp:first_marketed_in |
1953
|
| gptkbp:has_black_box_warning |
increased mortality in elderly patients with dementia-related psychosis
|
| https://www.w3.org/2000/01/rdf-schema#label |
Chlorpromazine hydrochloride
|
| gptkbp:IUPACName |
2-chloro-N,N-dimethyl-10H-phenothiazine-10-ethanamine hydrochloride
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
dopamine D2 receptor antagonist
antagonist at histamine H1 receptors antagonist at muscarinic acetylcholine receptors |
| gptkbp:meltingPoint |
195-198°C
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
355.33 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
71416
CHEBI:3647 DB00477 |
| gptkbp:routeOfAdministration |
oral
intramuscular intravenous |
| gptkbp:sideEffect |
weight gain
hypotension sedation photosensitivity extrapyramidal symptoms anticholinergic effects |
| gptkbp:synonym |
gptkb:Largactil
gptkb:Thorazine |
| gptkbp:UNII |
U3P01618RT
|
| gptkbp:usedFor |
nausea
schizophrenia vomiting psychotic disorders severe behavioral problems in children manic phase of bipolar disorder |
| gptkbp:bfsParent |
gptkb:Thorazine
|
| gptkbp:bfsLayer |
6
|